Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Queensland Health
Boehringer Ingelheim
AstraZeneca
Federal Trade Commission
Farmers Insurance
Fish and Richardson
Merck
Moodys

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022021

« Back to Dashboard

NDA 022021 describes ALTACE, which is a drug marketed by King Pharms Llc and King Pfizer and is included in two NDAs. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the ALTACE profile page.

The generic ingredient in ALTACE is ramipril. There are nineteen drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the ramipril profile page.
Summary for 022021
Tradename:ALTACE
Applicant:King Pfizer
Ingredient:ramipril
Patents:1
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 022021

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Feb 27, 2007TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Aug 30, 2020Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Feb 27, 2007TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Aug 30, 2020Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Feb 27, 2007TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Aug 30, 2020Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH

Expired US Patents for NDA 022021

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
King Pfizer ALTACE ramipril TABLET;ORAL 022021-004 Feb 27, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-002 Feb 27, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-001 Feb 27, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-003 Feb 27, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Cipla
Federal Trade Commission
QuintilesIMS
Colorcon
Accenture
McKesson
Teva
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.